Role of alcohol septal ablation in treatment of obstructive hypertrophic cardiomyopathy
- 1 February 2000
- journal article
- Published by Elsevier in The Lancet
- Vol. 355 (9202) , 425-426
- https://doi.org/10.1016/s0140-6736(00)82005-x
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Efficacy of Implantable Cardioverter–Defibrillators for the Prevention of Sudden Death in Patients with Hypertrophic CardiomyopathyNew England Journal of Medicine, 2000
- Electromechanical left ventricular behavior after nonsurgical septal reduction in patients with hypertrophic obstructive cardiomyopathyJournal of the American College of Cardiology, 1999
- Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathyEuropean Heart Journal, 1999
- Assessment of Permanent Dual-Chamber Pacing as a Treatment for Drug-Refractory Symptomatic Patients With Obstructive Hypertrophic CardiomyopathyCirculation, 1999
- Changes in Left Ventricular Diastolic Function 6 Months After Nonsurgical Septal Reduction Therapy for Hypertrophic Obstructive CardiomyopathyCirculation, 1999
- Echocardiography-Guided Ethanol Septal Reduction for Hypertrophic Obstructive CardiomyopathyCirculation, 1998
- Percutaneous Transluminal Septal Myocardial Ablation in Hypertrophic Obstructive Cardiomyopathy: Acute Results and 3-Month Follow-Up in 25 PatientsJournal of the American College of Cardiology, 1998
- Hypertrophic cardiomyopathyThe Lancet, 1997
- Nonsurgical Septal Reduction for Hypertrophic Obstructive CardiomyopathyCirculation, 1997
- Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathyThe Lancet, 1995